文献速递消化系统肿瘤

胃癌不同淋巴结分期系统预后效能比较分析

[Comparative analysis of prognostic performance among different lymph node staging systems in gastric cancer].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2026-01-01

该回顾性研究纳入200例D2根治术胃癌患者,比较pN、LNR、LODDS和sN四种淋巴结分期系统的预后预测效能。sN分期将阳性淋巴结数量与解剖分布结合,其5年生存预测AUC为0.789、C指数0.763、AIC 380.395,均优于其他三种分期系统,可作为术后风险分层实用工具。

要点

  • sN分期预测5年生存AUC为0.789,高于pN的0.751、LNR和LODDS的0.757。
  • pN分期中pN0与pN1、pN1与pN2、pN0与pN2、pN3a与pN3b生存差异均无统计学意义。
  • LNR、LODDS和sN三个亚组间生存率差异均有统计学意义(均P<0.001)。

核心结论

  • sN分期整合阳性淋巴结数量与转移部位,对D2根治术胃癌患者长期生存预测优于传统pN、LNR和LODDS分期。
  • sN分期可作为D2根治术胃癌患者术后风险分层的实用工具。

研究设计与样本

  • 回顾性纳入2014年1月至2019年12月中国医学科学院肿瘤医院完成D2根治术的胃癌患者200例。
  • 分别按第8版AJCC TNM的pN分期、LNR分期、LODDS分期和sN分期进行分期。
  • 采用Log-rank检验比较亚组生存率,Cox比例风险模型分析独立影响因素。
  • 通过时间依赖性ROC的AUC、C指数和AIC评价预后预测效能及拟合优度。

主要发现

  • pN0、pN1、pN2、pN3a、pN3b期分别44、32、55、33、34例,5年生存率分别为95.0%、90.3%、85.6%、56.3%、40.7%。
  • LNR1、LNR2、LNR3期分别116、36、46例,5年生存率分别为89.5%、73.3%、40.4%。
  • LODDS1、LODDS2、LODDS3期分别117、35、46例,5年生存率分别为89.5%、73.2%、40.4%。
  • sN1、sN2、sN3期分别93、50、55例,5年生存率分别为94.3%、76.5%、46.3%。
  • pN、LNR、LODDS和sN分期预测5年生存的AUC分别为0.751、0.757、0.757、0.789,C指数分别为0.752、0.754、0.754、0.763,AIC分别为384.544、381.981、381.913、380.395。

关键数值与推荐

  • pN分期中pN0与pN1、pN1与pN2、pN0与pN2、pN3a与pN3b亚组生存率差异均无统计学意义(均P>0.05)。
  • LNR、LODDS及sN分期中3组患者间生存率差异均有统计学意义(均P<0.001)。
  • 多因素Cox回归显示pN、LNR、LODDS和sN分期均为生存时间的独立影响因素(均P<0.05)。

临床怎么用

  • 对D2根治术胃癌患者,可考虑采用sN分期进行术后长期生存风险分层。
  • sN分期整合淋巴结数量与解剖分布,预测效能优于传统pN、LNR和LODDS分期。

局限性

  • 本研究为单中心回顾性分析,样本量200例,结论需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To establish a lymph node staging system based on the number of metastatic lymph nodes and their anatomical distribution (sN), and to evaluate its prognostic predictive performance in gastric cancer patients undergoing D2 radical resection. Methods: A retrospective analysis was conducted on 200 patients who underwent D2 radical gastrectomy for gastric cancer at the Cancer Hospital, Chinese Academy of Medical Sciences, between January 2014 and December 2019. Patients were staged according to four lymph node staging methods: pathological regional lymph node (pN) staging defined by the 8th edition of the American Joint Committee on Cancer (AJCC) TNM classification, lymph node ratio (LNR), log odds of positive lymph nodes (LODDS), and sN staging system. Survival differences among subgroups were compared using the log-rank test. Independent prognostic factors for survival were identified using the Cox proportional hazard model. The prognostic performance and model fit of each staging system were evaluated using the area under the time-dependent receiver operating characteristic (ROC) curve, concordance index (C-index), and Akaike information criterion (AIC). Results: Among the 200 patients, 44, 32, 55, 33, and 34 patients were classified as pN0, pN1, pN2, pN3a, and pN3b, respectively, with corresponding 5-year survival rates of 95.0%, 90.3%, 85.6%, 56.3%, and 40.7%, respectively. No significant differences in survival were observed between the pN0 and pN1 groups, pN1 and pN2 groups, pN0 and pN2 groups, or pN3a and pN3b groups (all P>0.05). According to LNR staging, 116, 36, and 46 patients were classified as LNR1, LNR2, and LNR3, with 5-year survival rates of 89.5%, 73.3%, and 40.4%, respectively. According to LODDS staging, 117, 35, and 46 patients were classified as LODDS1, LODDS2, and LODDS3, with corresponding 5-year survival rates of 89.5%, 73.2%, and 40.4%, respectively. According to the sN staging system, 93 patients were classified as sN1, 50 as sN2, and 55 as sN3, with corresponding 5-year survival rates of 94.3%, 76.5%, and 46.3%, respectively. Significant survival differences were observed among the three subgroups of the LNR, LODDS, and sN staging systems (all P<0.001). Multivariate Cox regression analysis demonstrated that pN, LNR, LODDS, and sN staging systems were independent influencing factors for overall survival (all P<0.05), although no significant differences were observed in the pN1 and pN2 subgroups of the pN staging system (all P>0.05). The AUCs for predicting the 5-year survival using the pN, LNR, LODDS, and sN staging systems were 0.751, 0.757, 0.757, and 0.789, respectively; the corresponding C-index values were 0.752, 0.754, 0.754, and 0.763; and the AIC values were 384.544, 381.981, 381.913, and 380.395, respectively. Conclusions: The sN staging system, which integrates the number and anatomical location of metastatic lymph nodes, demonstrates superior performance in long-term survival prediction compared with traditional pN, LNR, and LODDS staging systems for gastric cancer patients undergoing D2 radical gastrectomy. It may serve as a practical tool for postoperative risk stratification in this patient population. 目的: 构建基于转移淋巴结数目及其解剖位置分布特征的淋巴结分期系统(sN),并评价其对D2根治术胃癌患者的预后预测效能。 方法: 回顾性纳入2014年1月至2019年12月在中国医学科学院肿瘤医院完成D2根治术的胃癌患者200例,分别按照第8版美国癌症联合委员会TNM分期标准定义的病理区域淋巴结(pN)分期、淋巴结转移率(LNR)分期、阳性淋巴结对数比值(LODDS)分期和sN分期4种方法进行分期。采用Log rank检验比较各亚组间生存率,采用Cox比例风险模型明确生存时间的影响因素,通过时间依赖性受试者操作特征曲线的曲线下面积(AUC)、C指数和赤池信息准则(AIC)评价不同淋巴结分期方法的预后预测效能及拟合优度。 结果: 200例胃癌患者,pN分期为pN0期44例,pN1期32例,pN2期55例,pN3a期33例,pN3b期34例,5年生存率分别为95.0%、90.3%、85.6%、56.3%和40.7%,其中pN0期与pN1期、pN1期与pN2期、pN0期与pN2期、pN3a期与pN3b期患者的生存率差异无统计学意义(均P>0.05)。LNR分期为LNR1期116例,LNR2期36例,LNR3期46例,5年生存率分别为89.5%、73.3%和40.4%。LODDS分期为LODDS1期117例,LODDS2期35例,LODDS3期46例,5年生存率分别为89.5%、73.2%和40.4%。sN分期为sN1期93例,sN2期50例,sN3期55例,5年生存率分别为94.3%、76.5%和46.3%。LNR分期、LODDS分期及sN分期中3组患者间生存率差异均有统计学意义(均P<0.001)。多因素Cox回归分析显示,pN分期、LNR分期、LODDS分期和sN分期均为D2根治术胃癌患者生存时间的独立影响因素(均P<0.05),但pN分期中的pN1期与pN2期亚组无统计学意义(均P>0.05)。pN分期、LNR分期、LODDS分期和sN分期预测D2根治术胃癌患者5年生存的AUC分别为0.751、0.757、0.757和0.789,C指数分别为0.752、0.754、0.754和0.763,AIC分别为384.544、381.981、381.913和380.395。 结论: sN分期将阳性淋巴结数量和转移部位相结合,在D2根治术胃癌患者的长期生存预测中,比传统pN分期、LNR分期和LODDS分期具有显著优势,可作为D2根治术胃癌患者风险分层的实用工具。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Qiao XX, Liu QM, Wang YF, et al. [Comparative analysis of prognostic performance among different lymph node staging systems in gastric cancer]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42151087. doi:10.3760/cma.j.cn112152-20250820-00410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。